H. Lundbeck AS (FRA:LDBA) Net Interest Margin (Bank Only) %


FRA:LDBA H. Lundbeck AS FRA:LDBA
81 GF Score
Price €5.93
GF Value €6.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is H. Lundbeck AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:LDBA
81GF Score
H. Lundbeck AS FRA:LDBA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.93 is trading 6.1% below its estimated GF Value™ of €6.31. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for FRA:LDBA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €6.31 vs. price of €5.93 (6.1% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
81GF Score

Get the complete analysis for FRA:LDBA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.93
Price
€6.31
GF Value